Buscar
Savara Inc
SVRAAñadir a la lista de seguimiento
5.460USD
-0.080-1.44%
Cierre 07-31 16:00（ET）Cotizaciones retrasadas 15 min
1.12BCap. mercado
PérdidaP/E TTM
Más Datos de Savara Inc Compañía
Savara Inc. is a clinical-stage biopharmaceutical company. The Company is focused on rare respiratory diseases. The Company’s lead program, molgramostim inhalation solution (MOLBREEVI or molgramostim), is an inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). MOLBREEVI is an inhaled formulation of recombinant human GM-CSF and is being developed for the treatment of aPAP. MOLBREEVI is administered once daily by inhalation via a high efficiency nebulizer, the eFlow Nebulizer System (PARI Pharma GmbH). Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the accumulation of surfactant in the alveoli (or air sacs) of the lungs. The Company is engaged in the advancement of the MOLBREEVI aPAP program and the Phase III IMPALA-2 clinical trial and outsourcing capital-intensive operations.
Información de Savara Inc
Símbolo de cotizaciónSVRA
Nombre de la empresaSavara Inc
Fecha de salida a bolsaJun 25, 2001
Director ejecutivoPauls (Matthew)
Número de empleados59
Tipo de seguridadOrdinary Share
Fin del año fiscalJun 25
Dirección6836 Bee Cave Road
CiudadAUSTIN
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal78746
Teléfono151285113796
Sitio Webhttps://savarapharma.com/
Símbolo de cotizaciónSVRA
Fecha de salida a bolsaJun 25, 2001
Director ejecutivoPauls (Matthew)
Ejecutivos de Savara Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. David A. Ramsay
Mr. David A. Ramsay
Independent Director
Independent Director
2.49M
--
Mr. Robert Matthew (Rob) Lutz
Mr. Robert Matthew (Rob) Lutz
Chief Operating Officer
Chief Operating Officer
193.98K
+82.48%
Ms. Anne Erickson
Ms. Anne Erickson
Chief Business Officer
Chief Business Officer
132.03K
-47.69%
Mr. Braden Parker
Mr. Braden Parker
Chief Commercial Officer
Chief Commercial Officer
105.00K
+19.05%
Mr. Matthew (Matt) Pauls, J.D.
Mr. Matthew (Matt) Pauls, J.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Mr. David L. Lowrance, CPA
Mr. David L. Lowrance, CPA
Chief Financial and Administrative Officer, Secretary
Chief Financial and Administrative Officer, Secretary
--
--
Mr. Nevan Charles Elam, J.D.
Mr. Nevan Charles Elam, J.D.
Independent Director
Independent Director
--
--
Mr. Richard J. (Rick) Hawkins
Mr. Richard J. (Rick) Hawkins
Independent Director
Independent Director
--
--
Dr. Joseph S. (Joe) Mccracken, Ph.D.
Dr. Joseph S. (Joe) Mccracken, Ph.D.
Lead Independent Director
Lead Independent Director
--
--
Dr. Annigje (An) van Es-Johansson, M.D.
Dr. Annigje (An) van Es-Johansson, M.D.
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. David A. Ramsay
Mr. David A. Ramsay
Independent Director
Independent Director
2.49M
--
Mr. Robert Matthew (Rob) Lutz
Mr. Robert Matthew (Rob) Lutz
Chief Operating Officer
Chief Operating Officer
193.98K
+82.48%
Ms. Anne Erickson
Ms. Anne Erickson
Chief Business Officer
Chief Business Officer
132.03K
-47.69%
Mr. Braden Parker
Mr. Braden Parker
Chief Commercial Officer
Chief Commercial Officer
105.00K
+19.05%
Mr. Matthew (Matt) Pauls, J.D.
Mr. Matthew (Matt) Pauls, J.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Mr. David L. Lowrance, CPA
Mr. David L. Lowrance, CPA
Chief Financial and Administrative Officer, Secretary
Chief Financial and Administrative Officer, Secretary
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Savara Inc?
Los cinco principales accionistas de Savara Inc son: Mr. David A. Ramsay
¿Cuántas instituciones poseen acciones de Savara Inc (SVRA)?
A fecha de 2026Q1, 324 instituciones poseen acciones de Savara Inc, con un valor de mercado combinado de aproximadamente 213.87M, lo que representa el 104.36% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en 19143564.00.